Drug Profile

ASP 0598

Alternative Names: ASP-0598; AU-935

Latest Information Update: 09 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Auration Biotech
Developer Astellas Pharma
Class Growth factors; Intercellular signalling peptides and proteins; Recombinant proteins
Mechanism of Action Epidermal growth factor receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Ear disorders

Most Recent Events

31 Jul 2023 Discontinued - Phase-I for Ear disorders in Japan (Otic) (Astellas Pharma pipeline, August 2023)
31 Jul 2023 Discontinued - Phase-I/II for Ear disorders (In the elderly, In adults) in USA (Otic) (Astellas Pharma pipeline, August 2023)
28 Feb 2023 No recent reports of development identified for phase-I development in Ear disorders in Japan (Otic, Gel)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com